CCX 354
Alternative Names: 2941266; CCX354; CCX354-C; GSK-2941266Latest Information Update: 05 Nov 2023
At a glance
- Originator ChemoCentryx
- Class Antirheumatics; Small molecules
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA (PO, Tablet)
- 17 Jun 2015 Clinical development for rheumatoid arthritis is ongoing
- 14 Mar 2014 ChemoCentryx completes two phase I trials in Rheumatoid arthritis (in volunteers) in USA before March 2014